Latest Intelligence on Cardiovascular and Diabetes in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche/DeCODE: a long-term challenge for obesity and anxiety

Published By Datamonitor
14 Sep 2001
CommentWire
CommentWire

Siemens: AcuNav advances cardiac imaging

Published By Datamonitor
28 Sep 2001
CommentWire
CommentWire

Roche: stopping Xenical from slimming down

Published By Datamonitor
10 Oct 2001
CommentWire
CommentWire

AHP/Bayer: Baycol unlikely to mirror fen-phen

Published By Datamonitor
24 Oct 2001
CommentWire
CommentWire

Roche: Xeloda gets warning on warfarin interaction

Like many drugs, and some foods, Xeloda interacts negatively with popular anticoagulant warfarin. This may reduce the use of Xeloda in cancer patients requiring anticoagulation. It also highlights the potential of AstraZeneca's new oral anticoagulant, ximelagatran, which is currently undergoing phase III trials and is not associated with the interactions that plague warfarin.

Published By Datamonitor
07 Nov 2001
CommentWire
CommentWire

Boehringer Ingelheim: stroke drug may harm patients

The aptiganel results are just the latest in a string of disappointing results for neuroprotective agents in acute stroke. This casts serious doubt on this drug class' role in acute stroke, dashing early hopes that neuroprotective agents would fulfill a major unmet need in the anti-thrombosis market.

Published By Datamonitor
05 Dec 2001
CommentWire
CommentWire

Diabetes: maternal smoking is a risk factor

The data shows that maternal smoking during pregnancy is a risk factor for the development of early onset diabetes in offspring. Independently, cigarette smoking as a young adult can also increase the risk of subsequent diabetes. Given the huge economic impact of diabetes, it's clear that governments must do more to deter people from smoking.

Published By Datamonitor
08 Jan 2002
CommentWire
CommentWire

Pharmacia: seeking to deCODE pharmacogenomics

Pharmacia has followed Roche's example in teaming up with deCODE, in a deal that confirms Pharmacia's developing focus on the potential of pharmacogenomics. The company's many alliances in the field should help it launch new genomics-derived drugs, as well as cutting development costs and improving patient targeting.

Published By Datamonitor
16 Jan 2002
CommentWire
CommentWire

Aventis: cardiovascular success faces future threats

Lovenox and Delix/Tritace were both key products in 2001. While these blockbusters should remain strong revenue generators through 2004, they face serious market threats. Meanwhile, Aventis' new ACE/NEP inhibitor, expected to launch around 2004, could face strong competition from BMS' Vanlev, which is widely predicted to achieve blockbuster status despite regulatory problems.

Published By Datamonitor
13 Feb 2002
CommentWire
CommentWire

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor
01 Mar 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.